Theracryf Plc (AIM:TCF)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2400
-0.0100 (-4.17%)
Aug 7, 2025, 4:35 PM GMT+1
-4.17%
Market Cap5.11M
Revenue (ttm)n/a
Net Income (ttm)-1.94M
Shares Out2.13B
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,124,255
Average Volume4,641,422
Open0.2449
Previous Close0.2400
Day's Range0.2300 - 0.2500
52-Week Range0.2000 - 1.2500
Beta1.23
RSI48.03
Earnings DateAug 28, 2025

About Theseus Pharmaceuticals

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 9
Stock Exchange London Stock Exchange AIM
Ticker Symbol TCF
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.